Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures

Cardiff Oncology | May 27, 2020

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million. Under the agreement, Acorn Bioventures has agreed to purchase in a registered direct offering 1,205,400 shares of common stock and in a concurrent private placement, warrants to purchase 482,160 shares of common stock for a combined purchased price at market of $2.074 per share.  In a concurrent private placement, Acorn agreed to purchase warrants to purchase 482,160 shares of common stock. The warrants will be exercisable six months following the date of issuance, will expire on the five year anniversary of the initial exercise date and have an exercise price of $2.024 per share. Cardiff intends to use the net proceeds from the registered direct offering and concurrent private placement to rapidly advance its onvansertib clinical development programs and to provide additional working capital.

Spotlight

Genetic engineering, sometimes called genetic modification, is the process of altering the DNA? in an organism’s genome?.This may mean changing one base pair? (A-T or C-G), deleting a whole region of DNA, or introducing an additional copy of a gene?. It may also mean extracting DNA from another organism’s genome and combining it with the DNA of that individual. Genetic engineering is used by scientists to enhance or modify the characteristics of an individual organism. Genetic engineering can be applied to any organism, from a virus? to a sheep.

Spotlight

Genetic engineering, sometimes called genetic modification, is the process of altering the DNA? in an organism’s genome?.This may mean changing one base pair? (A-T or C-G), deleting a whole region of DNA, or introducing an additional copy of a gene?. It may also mean extracting DNA from another organism’s genome and combining it with the DNA of that individual. Genetic engineering is used by scientists to enhance or modify the characteristics of an individual organism. Genetic engineering can be applied to any organism, from a virus? to a sheep.

Related News

Access Biologicals Completes the First-ever Commercially Available COVID-19 Seroconversion Panel to Confirm SARS-CoV-2 Antibody Assays

PR Newswire | September 07, 2020

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without the independent data to help assess their analytical performance and enable comparisons between different testing methods. With Access Biologicals' seroconversion panel, diagnostic manufacturers, clinical laboratories and researchers will have a reliable benchmark against which they can develop, validate and troubleshoot other COVID-19 serological assays and testing. "An effective, sensitive and specific way to identify and confirm the SARS-CoV-2 infection is urgently needed," said Mike Crowley, Managing Director Access Biologicals. "Our COVID-19 seroconversion panel will help serological assays bridge the gap through precise validation, establishing sensitivity and helping determine the pre-seroconversion window period, which is the time after infection and before seroconversion, when antibodies appear." Collected in a longitudinal series, the Access Biologicals COVID-19 seroconversion panel consists of 14 members (units) of a unique human plasma sample drawn from a single donor during a developing SARS-CoV-2 infection. The panel illustrates the onset and decline of IgM, IgG and Ig total SARS-CoV-2 virus antibody titers over a period of 87 days.

Read More

MEDICAL

HealthPartners, Helix partner to create DNA testing program that helps families better understand their genetic health

Helix | March 09, 2022

HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states. The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk earlier and potentially mitigate serious disease. In similar programs, as many as 1 in 75 participants were found to be at risk for a serious health issue, of which 90 percent would not have been discovered through traditional practice. We see population genomics as a critical step in our efforts to improve the health of the communities we serve across Minnesota and surrounding states, By understanding the role genetics play in an individual's health, we can deliver more personalized care and improve the lives of our patients." Steve Connelly, MD, co-executive medical director at HealthPartners. The program aligns with HealthPartners ongoing drive to deliver simple, personalized, affordable care. The program will be strictly voluntary and will come at no cost to the patient. It's a partnership both HealthPartners and Helix say will help advance precision medicine and greater health equity. We are thrilled to partner deeply with one of the leading integrated delivery networks in the nation. We are excited to enable population access to preventable and actionable genetic insights and to empower providers and patients to make more informed medical decisions, The partnership will also generate cutting edge insights on the best ways to improve quality outcomes, close care gaps and lower the cost of care." James Lu, MD, PhD, CEO and co-founder of Helix. HealthPartners will leverage Helix's end-to-end genomic platform and unique Sequence Once, Query OftenTM model. It allows patient access to genetic data in a cost-efficient manner while also advancing ongoing genomics research. Helix has helped to launch similar programs at the Mayo Clinic, Renown Health and most recently, the Medical University of South Carolina. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Through its CLIA / CAP laboratory, its end-to-end workflow, and data analytics platforms, Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision making. About HealthPartners HealthPartners is dedicated to improving health and well-being in partnership with members, patients and the community. As an integrated health system, it provides care to more than one million patients and coverage to more than 1.8 million medical and dental health plan members nationwide. HealthPartners also provides medical education and conducts research through HealthPartners Institute.

Read More

RESEARCH

Quantgene Demonstrates Game-Changing Sequencing Precision in GENES, A Leading Scientific Journal

Quantgene | June 08, 2021

Quantgene, biotechnology, cloud, and AI company located in Santa Monica, CA, and Berlin, Germany, has demonstrated the most exact gene sequencing yet published in the industry, as shown in the February edition of GENES, a major scientific journal in medical genomics. "Precision Genomics is revolutionizing medicine, but it is being hampered by a lack of rapid, accurate, and easily accessible technology," said Jo Bhakdi, CEO of Quantgene. "Today, the protection of human life is dependent on the advancement of precision genomics, and we are excited to open a new chapter in genomic testing and less invasive cancer screening." DEEPGENTM reduced error rates on Illumina NovaSeq platforms hundreds of times by integrating new chemistry with large-scale cloud processing, mathematically enhanced error reduction, and statistically optimized genomic mapping, signaling an innovative approach ahead for cancer testing. Quantgene's latest innovation is a significant step forward in evidence-based healthcare and precision medicine. Quantgene's DEEPGEN technology was thoroughly investigated in its peer-reviewed publication, which included a series of technical validations. According to the publication, the system detects somatic variations in DNA fragments with an accuracy of more than 1 in 1000 fragments, with high repeatability and very low false-positive results. This degree of accuracy has previously only been proven in a peer-reviewed setting for systems that examined a small number of genomic regions. DEEPGEN's technology covers around 70,000 locations and includes a wide range of FDA-approved cancer targets. The results of Quantgene represent a significant advance in the identification of cancer signals in the blood using liquid biopsy and next-generation sequencing technology. Liquid biopsy can be a less invasive and more accurate method of diagnosing different forms of cancer. In oncology, it may also be used to aid physicians in early cancer detection, companion diagnostics, and identifying minimum residual disease. "This is a crucial step forward in precision medicine. Quantgene provides the industry with a more powerful tool to diagnose cancer and other serious diseases earlier than ever before by achieving single-molecule sequencing precision ", said Jo Bhakdi, CEO of Quantgene. About Quantgene Quantgene has emerged as a technical leader in single-molecule precision sequencing over the last six years. To better protect patients from cancer, the company combines deep genomic, cloud, and AI technologies with innovative preventative medicine solutions. Its objective is to increase the healthy human lifespan by ten years within the next ten years.

Read More